SCHEMBL176393

SCHEMBL176393

C1=CCCC2CNNC2=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2076404 0.69
SCHEMBL1979258 0.69
SCHEMBL3699545 0.68
SCHEMBL8831837 0.68
SCHEMBL29256069 0.68
SCHEMBL3596828 0.64
SCHEMBL4982271 0.63
Ammonia Solution, Strong SCHEMBL4749964 0.62
SCHEMBL433934 0.60
SCHEMBL19610207 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5221998-A None JP disclosed
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS ACTIO BIOSCIENCES, INC. 2025-10-09 US disclosed
EP-2957560-B1 PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID-2 AGONISTS ALLERGAN INC (US) 2017-08-02 EP disclosed
US-9670216-B2 Cannabinoid-2 agonists ALLERGAN, INC. (US) 2017-06-06 US disclosed
EP-2957560-A1 PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID-2 AGONISTS ALLERGAN, INC. (US) 2015-12-23 EP disclosed
US-20150284400-A1 CANNABINOID-2 AGONISTS ALLERGAN, INC. 2015-10-08 US disclosed
EP-2534137-B1 PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID-2 AGONISTS ALLERGAN INC (US) 2015-09-16 EP disclosed
US-9062004-B2 Cannabinoid-2 agonists ALLERGAN, INC. (US) 2015-06-23 US disclosed
US-20130059848-A1 CANNABINOID-2 AGONISTS ALLERGAN, INC (US) 2013-03-07 US disclosed
US-5387693-A Intermediates for inhibitors of cholesterol biosynthesis ORTHO PHARMACEUTICAL CORPORATION (US) 1995-02-07 US disclosed
US-5315012-A Prevention of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis ORTHO PHARMACEUTICAL CORPORATION (US) 1994-05-24 US disclosed
US-5315012-A Prevention of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis ORTHO PHARMACEUTICAL CORPORATION (US) 1994-05-24 US disclosed
US-5250561-A Anticholesterool agents; prevention of hyperlipoproteinemia and atherosclerosis ORTHO PHARMACEUTICAL CORPORATION (US) 1993-10-05 US disclosed
US-5250561-A Anticholesterool agents; prevention of hyperlipoproteinemia and atherosclerosis ORTHO PHARMACEUTICAL CORPORATION (US) 1993-10-05 US disclosed
JP-H05221998-A WETRAHYDROINDAZOLE, TETRAHYDROCYCLOPENTAPYRAZOLE AND HEXAHYDROCYCLOHEPTA PYRAZOLE COMPOUN, AND THEIR USE AS HMG-COA REDUCTASE INHIBITOR ORTHO PHARMACEUT CORP 1993-08-31 JP disclosed
EP-0529854-A2 Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-COA reductase inhibitors ORTHO PHARMACEUTICAL CORPORATION (US) 1993-03-03 EP disclosed
EP-0529854-A2 Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-COA reductase inhibitors ORTHO PHARMACEUTICAL CORPORATION (US) 1993-03-03 EP disclosed
US-5134155-A Anticholesterol ORTHO PHARMACEUTICAL CORPORATION (US) 1992-07-28 US disclosed
US-5134155-A Anticholesterol ORTHO PHARMACEUTICAL CORPORATION (US) 1992-07-28 US disclosed